2-cyclohexyl-4-phenyl-6-trifluoromethoxy-1,2,3,4-tetrahydro-quinoline | 745818-12-6

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二芳基庚烷
• 英文名称: 2-cyclohexyl-4-phenyl-6-trifluoromethoxy-1,2,3,4-tetrahydro-quinoline
• 英文别名: 2-Cyclohexyl-4-phenyl-6-(trifluoromethoxy)-1,2,3,4-tetrahydroquinoline
• CAS: 745818-12-6
• 化学式: C₂₂H₂₄F₃NO
• 分子量: 375.434
• InChiKey: QOBMHEPOQMJGRZ-UHFFFAOYSA-N

物化性质

• 沸点：
  430.5±45.0 °C(Predicted)
• 密度：
  1.184±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  7.4
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] QUINOLINE DERIVATIVE AND THEIR USE FOR MODULATION OF LXR ACTIVITY<br/>[FR] MODULATION DE L'ACTIVITE DE RECEPTEURS NUCLEAIRES
  申请人：CAREX S A

  公开号：WO2004072042A2

  公开（公告）日：2004-08-26

  The present invention relates to specific compounds and pharmaceutically acceptable salts thereof; methods for synthesizing these compounds; compositions comprising at least one of these compounds or a pharmaceutically acceptable salt thereof; and methods for modulating liver-X receptors (LXRs) activity. The present invention further concerns methods for treating and/or preventing a disease or disorder selected from the group consisting of dyslipidemia, including hyperlipidemia, dyslipoproteinemia, including hyperlipoproteinemia, disorders related to cholesterol or bile acid metabolisms, including hypercholesterolemia, gall stone or gall bladder disorders, cardiovascular disease, including atherosclerotic cardiovascular diseases, coronary artery diseases, peripheral vascular diseases, cerebrovascular diseases, thrombotic disorders, restenosis or septic shock, CNS diseases including those affecting cognitive function or age related disorders such as Alzheimer's disease, Syndrome X, a liver-X receptor-associated disorder, obesity, pancreatitis, hypertension, renal disease, cancer, rheumatoid arthritis, inflammation, skin proliferative disorders, including psoriasis, atopic dermatitis or acne, and sexual impotence, comprising administering a therapeutically effective amount of a composition comprising at least one compound or a pharmaceutically acceptable salt thereof of the invention.